Xynomic Pharmaceuticals, Inc.

//   • 研发客2025年资本市场预期调研发现，50%的受访机构表示，推荐被投企业去美股上市，其余50%选择了港股和A股（含科创板）；37.5%的企业家认为，美股上市是更适合的选择，选择港股IPO的仅12.5%。 2025开年，亚盛医药以每份美国存托股份17.25美元的发行价在美国纳斯达克挂牌上市，获得近1.2亿美元的融资。截止2月11日收盘，亚盛医药每份存托股份股价已达到18.90元，上涨幅度接近10%；公司市值接近15亿美元。 良好的股价表现，在距离上一轮赴美上市高峰期的五年后，提振了更多中国生物医药企业去美国市场上市的信心——这也在研发客2025年资本市场预期调研数据中得到验证。投资人和企业家的心态正在发生微妙的变化。 与往年相比，倾向于企业在美国上市的投资机构和企业家数量明显提升。其中有50%的受访机构表示，推荐被投企业去美股上市，其余50%选择了港股（40%）和A股（含科创板）。企业家也做出了相似的决策，37.5%的企业家认为，美股上市是更适合的选择，选择港股IPO的仅12.5%。（见下图） 这与过去6年的调研结果大相径庭。（见下图） 重拾赴美IPO的信心，与过去两年美国资本市场强势表现，以及全球流动性宽裕密不可分。据万得数据统计，截止2月11日，2023年至今纳斯达克指数累计上涨超过88%，领先于各大成熟市场。 推动股价上涨既有业绩的因素，也有估值的因素，而绝大部分来自对AI的想象、宽松预期以及对特朗普政策的提前展望。而当全球流动性宽裕（如美联储降息）时，美元资产收益率下降，国际资本倾向于流向新兴市场的高成长性行业。从过去一年中国创新药公司与全球制药巨头密集授权、NewCo交易频繁显现，可见一斑。 那么，美国资本市场是否适合中国生物制药公司？回顾过去20多年中国生物医药企业登陆美国资本市场的历史，其中既有光荣与梦想，也有失落与离场，以此作为后来者们的借鉴。 破冰：拓荒者的时代（2000~2010年） 时间倒回25年前的世纪初，中国生物医药产业尚在襁褓。也是在那时，全球互联网泡沫破灭，首批登陆华尔街的中国互联网企业股价大幅下跌，甚至退市，在华尔街的全球投资者亟待寻找新的中国创新故事。 科兴生物：疫苗出海“孤勇者” 2003年9月，在北京、香港等城市刚刚度过非典疫情危机之际，科兴生物悄然登陆美国OTCBB市场（2004年底转板美国证券交易所）。这家成立于1999年的中国生物医药企业，凭借甲肝灭活疫苗“孩尔来福”打开国门。该疫苗在2017年通过WHO预认证，也是目前国内唯一一款通过WHO认证的甲肝疫苗。但公司上市之初，却因“中国疫苗”的身份饱受质疑，股价徘徊在低位。 2009年，科兴研发的全球第一支甲型H1N1流感病毒裂解疫苗盼尔来福上市，股价一度冲上12美元。然而，技术突围未能化解资本市场的冷遇。2016年，科兴启动私有化，却因两大个人股东尹卫东与潘爱华的间控股权之争，陷入长达三年的停牌泥潭，最终在2019年2月于以6.47美元/股从纳斯达克市场黯然退市。 药明康德：CRO模式“摆渡人” 如果说科兴生物在美国资本市场借壳上市只是开胃菜，那么2007年8月，药明康德在纽交所的敲钟，则是正菜佳宴的开始。 创始人李革的愿景是打造“全球制药业的基础设施”。这家从4人实验室起步的公司，凭借“中国工程师红利”，将药物发现成本降至欧美1/3。上市首日涨幅超40%，外媒称“华尔街首次为中国的头脑买单”，这也意味着中国生物医药企业正式进入华尔街主流投资者的视野。 其实，华尔街看中的不是中国的技术，而是中国制造的性价比。药明康德如同一条摆渡船，将跨国药企的研发需求与中国产能连接，但其商业模式始终被诟病为“高级代工”，并不是真正的中国创新药企。 与科兴生物一样，同样因为对华尔街投资者给出的公司估值不认可，药明康德以33亿美元在2015年从美国市场私有化退市。但与科兴生物随后陷入股权争夺战不同，药明康德回归中国资本市场，药明系的市值合计一度超6000亿元，完成从“代工者”到“生态构建者”的跃迁。 先声药业：创新药的“悲情试水” 稍早于药明康德，先声药业于2007年4月登陆纽交所，成为中国首家在纽交所上市的生物和化学制药公司，并创下了当时亚洲最大规模的医药公司IPO纪录之一。 当时先声药业的资本故事，是其被誉为“中国首个靶向抗癌药”的抗肿瘤药恩度”（重组人血管内皮抑制素），但上市后因疗效争议，股价从14.5美元发行价跌至不足5美元。 此后，先声药业继续以大额资金投入的形式支撑创新药研发，而持续的高负债率让美国投资者对公司的估值始终保持谨慎态度。 但华尔街可能不懂中国创新药的艰难。2013年，先声药业以4.95亿美元私有化退市，转而深耕中枢神经、肿瘤和自免领域。2020年港股上市时，其自研的CDK4/6抑制剂已进入3期临床，市值较美股时期增长超5倍。 包括科兴生物、药明康德和先声药业，这一阶段的赴美企业，如同探路的纤夫，在技术、资本与文化的三重激流中负重前行。他们先后因估值过低而主动退市的困境揭示了一个残酷现实：没有硬核创新的“中国故事”，终难打动国际资本市场。 狂飙：黄金十年的荣光（2010~2020） 2015年之后，中国新药行业的发展按下了加速键。短短几年时间，诞生了一批创新企业，并努力登上全球竞争的舞台。国内一级市场融资估值水涨船高，美国资本市场也开始迎接这些真正来自中国创新者的野心。 百济神州：Biotech的“独立宣言” 2016年2月，百济神州登陆纳斯达克，募资1.82亿美元。百济神州的上市既是2016年美国IPO第一单，也是真正意义上第一家赴美上市的中国创新药公司。创始人王晓东博士曾宣言要做全球最好的抗癌药。当然，百济神州也一直在强调自己的全球化药企身份。 百济神州首日收盘价比发行价上涨18%，在当时中概股纷纷退市的背景下，可谓逆势而上。资本市场对以百济神州为代表的中国生物医药企业的耐心在2019年迎来回报——泽布替尼获FDA批准，成为首个“出海”成功的中国原研抗癌药。2021年12月15日，被称为中国创新药“一哥”的百济神州登陆科创板，成为全球首家在美股、港股、A股三地上市的生物医药公司。伴随百济神州的3次IPO，高瓴资本也成为了幕后的大赢家。 自2016年2月百济神州登陆纳斯达克，目前美股股价已翻10倍；2018年港股上市至今，股价表现突出，总市值达2700亿港元。 和黄医药：勤勉的耕耘者 百济神州在纳斯达克市场的良好表现，为后续中国生物医药创新赴美上市开了好头。紧随其后上市的是和黄医药，当时的发行价13.5美元，募资约1.0125亿美元。 呋喹替尼是和黄最耀眼的一款产品。2023年11月，呋喹替尼成功在美国获批。用于治疗既往曾接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗、抗血管内皮生长因子治疗，以及抗表皮生长因子受体治疗的成人转移性结直肠癌患者。也是继泽布替尼后，又一款中国研发的小分子抗癌药在美国获批。 目前，和黄医药共有10多个研发管线，并实现了在纳斯达克、伦敦证交所以及港交所三地上市。 再鼎医药：License-in的“资本魔术” 2017年9月，再鼎医药登陆纳斯达克，募资1.5亿美元。值得一提的是，招股书显示再鼎医药估值已高达8亿美元。 在还未有产品上市实现营收的情况下，再鼎医药成立短短三年就成功登陆纳斯达克。创始人杜莹博士的策略是“用资本换时间”：引进尼拉帕利（则乐）、奥拉帕利等海外临床后期产品，快速搭建商业化矩阵。 2020年，尼拉帕利在中国获批，当年营收突破2亿元，股价当年涨幅超225%。相对于百济神州注重"卖出去"，再鼎医药则侧重"买进来"。“License-in不是捷径，而是打通中外创新的桥梁。”杜莹强调。 再鼎的成功，催生了中国Biotech的“引进潮”，却也引发“伪创新”的争议。 传奇生物：CAR-T的“诺曼底登陆” 又过了三年，美国资本市场迎来中国生物医药企业上市高潮，相继有徐诺药业（2019年5月）、天境生物（2020年1月）、传奇生物（2020年6月）、亘喜生物（2021年1月）、天演药业（2021年2月）、拓臻生物（2021年2月）、康乃德生物（2021年3月）登陆以纳斯达克为代表的美国资本市场。 其中，传奇生物携CAR-T疗法西达基奥仑赛登陆纳斯达克，他们原本计划融资3亿美元，结果超额融资4.87亿美元。这股热情也是经历了过去三年创新药资本泡沫破灭的投资者所无法想象的。 据研发客不完全统计，2017~2020年，20余家中国生物医药公司赴美上市，总募资额超150亿美元。高瓴资本、红杉中国等机构重仓押注，催生“估值泡沫”。 2021年，压垮中国生物医药企业在美上市估值泡沫的稻草来袭，证券交易委员会（SEC）颁布《外国公司问责法案》，百济神州、再鼎医药等被列入“预摘牌名单”，多只国内生物医药企业股价单日跌幅超30%。关注中国生物医药企业的企业家和投资者发现：地缘政治已成中国Biotech的“达摩克利斯之剑”。 转折：退潮与再出发（2020至今） 2018年4月，港交所修订《上市规则》，新增第18A章，允许未盈利生物科技公司上市。自此，香港成为国内生物医药企业上市的首选地，截至2024年底，超70家企业借此登陆港股，募资总额逾千亿港元。 2019年7月，科创板开市，第五套标准对未盈利药企敞开大门。截至2023年，国内科创板生物医药板块总市值突破1.3万亿元，成为本土创新的资本引擎。 但香港市场的低流动性和科创板市场设置的高门槛，仍未让中国生物医药企业寻找到完全适宜其发展的优渥资本环境，美国资本市场仍将是后起的中国生物医药企业上市的重要选择之一。 2023~2024年，依然有几家中国Biotech公司陆续进入美国资本市场。其中，阿诺医药和硕迪生物以IPO的形式登陆纳斯达克，冠科美博和依生生物则以SPAC方式在纳斯达克上市。 未来，或许不再有“赴美潮”与“回归潮”的泾渭分明。研发客相信，在美股、港股与科创板交织的新生态中，中国生物医药的史诗，正翻开技术驱动全球化的下一页。 编辑 | 姚嘉 yao.jia@PharmaDJ.com  总第2341期 访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse after conventional chemotherapy regimens. This paradigm shift is characterized by the emergence of innovative therapies like CAR T-cell therapy and bispecific antibodies, which have demonstrated remarkable efficacy in targeting and eradicating lymphoma cells. CAR T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered to recognize and attack cancer cells. This personalized treatment has shown significant promise, especially for individuals who have undergone extensive previous therapies. One notable example is Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy approved for use in patients with relapsed or refractory follicular lymphoma. Clinical trials have highlighted its ability to induce durable remissions, with some patients experiencing long-term remission even after multiple prior therapies. LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the follicular lymphoma pipeline domain. Key Takeaways from the Follicular Lymphoma Pipeline Report DelveInsight's follicular lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for follicular lymphoma treatment. Key follicular lymphoma companies such as Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others are evaluating new follicular lymphoma drugs to improve the treatment landscape. Promising follicular lymphoma pipeline therapies such as Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others are under different phases of follicular lymphoma clinical trials. In August 2024, the company expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with FL who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024 based on the positive Phase III results. In June 2024, a consortium of Eugene Private Equity and Korea Development Bank Private Equity announced that they would acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million). In February 2024, Incyte announced that it had entered into an asset purchase agreement with MorphoSys AG, which gives Incyte exclusive global rights for tafasitamab. Incyte will now recognize revenue and cost for all US commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments. In September 2023, OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate. The ONM-501 first-in-human trial is a multicenter Phase Ia/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid tumors and lymphomas. OncoNano is the sponsor of the clinical trial, and Regeneron will supply cemiplimab. In May 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. Under the terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the Chinese territory. Janssen will make an upfront payment of USD 245 million that will be accounted for in the second quarter as a research and development expense. Additional future payments will be based upon achieving certain development, regulatory, and sales milestones, as well as tiered royalty payments on worldwide net trade sales, excluding Greater China. Request a sample and discover the recent advances in follicular lymphoma treatment drugs @ Follicular Lymphoma Pipeline Report The follicular lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage follicular lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the follicular lymphoma clinical trial landscape. Follicular Lymphoma Overview Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This cancer is characterized by the growth of abnormal lymphoid follicles, which can disrupt normal lymphatic function. While the exact causes of follicular lymphoma are not fully understood, certain factors may increase the risk, including age (most commonly affecting adults over 60), a family history of lymphoma, and potential environmental factors such as exposure to pesticides or chemicals. Symptoms of follicular lymphoma can vary widely but may include painless swelling of lymph nodes in the neck, armpit, or groin, unexplained weight loss, night sweats, fatigue, and fever. Some patients may remain asymptomatic for extended periods, as this type of lymphoma can progress slowly. Diagnosis typically involves a combination of physical examinations, blood tests, imaging studies (like CT scans), and a biopsy of affected lymph nodes. The biopsy helps determine the subtype and stage of the lymphoma, which is crucial for planning treatment. Treatment for follicular lymphoma depends on the stage of the disease and the patient's overall health. Options may include watchful waiting for asymptomatic cases, chemotherapy, immunotherapy (such as monoclonal antibodies), and targeted therapies. In some cases, stem cell transplants may be considered for patients with more aggressive forms or those who do not respond to initial treatments. Given the indolent nature of follicular lymphoma, ongoing management, and regular monitoring are vital for achieving the best possible outcomes. Find out more about follicular lymphoma treatment drugs @ Drugs for Follicular Lymphoma Treatment A snapshot of the Follicular Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging follicular lymphoma pipeline therapies @ Follicular Lymphoma Clinical Trials Follicular Lymphoma Therapeutics Assessment The follicular lymphoma pipeline report proffers an integral view of the follicular lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Follicular Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitors, Phosphatidylinositol 3 kinase gamma inhibitors, Emt protein-tyrosine kinase inhibitors, Interleukin 15 receptor agonists, Histone deacetylase inhibitors, Rad51 recombinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Enhancer of zeste homolog 2 protein inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death 1 receptor antagonists, T lymphocyte stimulants, Alkylating agents, DNA cross-linking agents Key Follicular Lymphoma Companies: Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others. Key Follicular Lymphoma Pipeline Therapies: Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others. Dive deep into rich insights for new drugs for follicular lymphoma treatment, visit @ Follicular Lymphoma Drugs Table of Contents For further information on the follicular lymphoma pipeline therapeutics, reach out @ Follicular Lymphoma Treatment Drugs Related Reports Follicular Lymphoma Market Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies including Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

中国上海 近日，印度知名制药企业瑞迪博士实验室（Dr. Reddy's）国际商务团队一行到访徐诺药业上海肿瘤临床医学研究中心，受到公司董事长兼首席执行官徐英霖先生及其商务团队的热情接待。此次访问旨在探讨双方在全球抗肿瘤药物领域的合作机会。 在座谈交流会上，徐诺药业商务团队与瑞迪博士实验室的代表就未来合作的可能性进行了深入探讨。双方一致表示，抗肿瘤药物研发是当前医药领域的重点方向，双方在该领域有着共同的目标和愿景。瑞迪博士实验室作为全球知名的制药企业，在抗肿瘤药物研发领域积累了丰富的经验和资源。徐诺药业则凭借艾贝司他等创新药物的研发实力，展现出了强大的市场竞争力。 双方期待在印度和新兴市场如拉丁美洲、南非等国家共同开展艾贝司他的研发与商业化合作。徐诺药业徐英霖先生表示：“我们很高兴有机会与瑞迪博士实验室这样的知名企业进行交流，这将使我们在为肿瘤患者提供更多优质产品方面又向前迈出了一步。我们的目标是在抗肿瘤药物领域建立起强大而全面的产品组合，为全球患者带来福音。” 关于徐诺 徐诺药业(南京)有限公司是一家以患者需求为导向专注开发抗肿瘤药物的全球性生物制药公司，在自主研发和License in（授权引进）双引擎驱动下，旨在为全球患者提供更有效的治疗方案。目前的产品管线主要包括三款候选药物，艾贝司他、 XP-105 和 XP-102。公司拥有这些药物的全球独家研发、生产和商业化权益。公司全球总部在南京，分别在上海、美国加州都设有办公室。公司创立团队曾在跨国生物制药公司（先灵、礼来、默克、罗氏、施贵宝等）从事研发、临床、商务等工作。公司联合创始人、董事长、首席执行官兼总裁徐英霖先生是一位成功的连续创业家，曾联合创办了两家美中生物制药公司并成功退出。此外，公司与Pharmacyclics / AbbVie，Boehringer Ingelheim和Janssen等知名跨国药企深度合作。 投资者关系、媒体和商务拓展请联系： angela.feng@xynomicpharma.com